Non-Small Lung Cancer

The FDA granted breakthrough therapy designation to patritumab deruxtecan for treatment of certain patients with non-small cell lung cancer.

The FDA approved ramucirumab in combination with erlotinib for first-line treatment of patients with metastatic non-small cell lung cancer who have EGFR exon 19 deletions or exon 21 L858R mutations.

Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

The addition of tislelizumab to first-line chemotherapy extended PFS among patients with nonsquamous non-small cell lung cancer, according to topline data from a randomized phase 3 trial released by the agent’s manufacturer.